Aldeyra Therapeutics stock experienced significant downward sell-offs following the receipt of Complete Response Letters (CRLs) from the U.S. FDA regarding the New Drug Application for reproxalap. Because investor expectations were heavily anchored on successful commercial approval for dry eye disease treatment, the regulatory delays and requests for further exploratory data triggered sharp market corrections and downward valuation adjustments.